[The development of self-adhesive low-ohm gel electrodes for the determination of bioelectric parameters].
Explore the source record for details and available documents.
Adhesiveness↗
Biomedical subjects
J Haustein
Publications and source records attributed to J Haustein.
[Cyanide detoxication by DL-glycerine aldehyde].
Explore the source record for details and available documents.
Animals↗
Elimination of Gd-DTPA by means of hemodialysis.
After intravenous administration of Gd-DTPA (0.1 mmol/kg) hemodialysis was performed five times within 6 days in a patient with endstage renal failure. During the fifth hemodialysis a blood sample of 5 ml was withdrawn and Gd-concentration was measured in plasma at 342.247 nm using the method of Inductively Coupled Plasma Atomic Emission Spectrometry. Gd-concentration measured in venous and arterial blood was 6 x 10(-6) mol/liter, corresponding to 1.5% of the dose administered. If these data can be confirmed in more patients with endstage renal failure, this is the proof of effective hemodialysis of Gd-DTPA in a clinical setting.
Adult↗
Tolerance data of Gd-DTPA: a review.
Gd-DTPA is the first paramagnetic contrast agent approved for clinical use in cranial and spinal MRI in the F.R.G., U.S.A., Japan and several other countries. After submission 13,439 patients were enrolled in standardized protocolled clinical trials. The observed adverse drug reactions (ADRs) after i.v. injection of Gd-DTPA were comparable to those after administration of iodinated non-ionic roentgen contrast media (CM). However, the overall incidence of ADRs after intravenous injection of 0.1 or 0.2 mmol/kg body weight Gd-DTPA was found to be even lower. Adverse events were observed in only 1.46% of the patients - or 1.14% if localized warmth is excluded. None of them was critical. There was no correlation between patient age and the incidence of ADRs. In patients with a known history of allergy the incidence of ADRs was increased by a factor 3-4, which is still lower than the incidence reported after intravenous administration of iodinated non-ionic roentgen CM to patients without known allergy. Good renal tolerance was seen in all patients, irrespective of pre-existing renal impairment. Fast bolus injections of Gd-DTPA were tolerated without added risk. The favorable safety profile is also reflected in the post marketing surveillance reports since Gd-DTPA became available as a commercial drug.
Contrast Media↗
Dermoid cyst with crystalline inclusions in adjacent cortex: an ultrastructural study.
Dermoids are rare tumors of the central nervous system. So far, no electron microscopic studies of these tumors have been available. We describe the histology and ultrastructure of a dermoid cyst in a patient with situs inversus and discuss the relationship of keratin and aseptic meningitis, a well-known complication. Histological examination showed an epidermal matrix with 2-4 layers, a cyst containing keratin and debris, some hairs and sebaceous glands. In some areas, chronic inflammation had destroyed the matrix of the cyst wall. Gliosis of the adjacent brain parenchyma was evident, as were eosinophilic rod-shaped crystals. Electron microscopy revealed gliosis with Rosenthal fibers in brain parenchyma adjacent to the tumor capsule. Intracellular osmiophilic, crystalline inclusions were prominent within this area. Glial cells and neuropil were spared. No gross intracellular pathology was seen.
Brain Neoplasms↗
Administration of gadopentetate dimeglumine in MR imaging of intracranial tumors: dosage and field strength.
PURPOSE: To investigate the efficacy of 0.025, 0.05 and 0.1 mmol/kg gadopentetate dimeglumine in MR imaging of patients with intracranial tumors at mid and high field strength. METHODS: In 88 patients, an open-label phase III multicenter dose-finding study was performed at 0.5, 1.0, and 1.5 T MR units. Before and after (5, 15, 25 minutes) intravenous administration of gadopentetate dimeglumine, imaging was performed with T1-weighted spin-echo sequences. RESULTS: With 0.1 mmol/kg yielding the highest values, tumor enhancement and numerical tumor/brain contrast showed dose-dependent 5-minute postcontrast values (P less than 0.05). Compared to 5-minute postcontrast values, there was no significant change at 15 and 25 minutes. Although the lowest values of enhancement were found at 0.5 T, differences in enhancement among the field strengths were not statistically significant. The numerical data were confirmed by visual assessment of tumor/brain contrast. Eighty to 90% of cases had diagnostically valuable enhancement at 0.1 mmol/kg, 50% at 0.05 mmol/kg, and 10% at 0.025 mmol/kg (P less than 0.05). There were no adverse events. CONCLUSION: Our results confirm that 0.1 mmol/kg gadopentetate dimeglumine is more effective at enhancing intracranial tumors than lower doses at mid and high field MR units.
Adult↗
The Werner syndrome: a case study.
We present the neuropathological data of a 49-year-old patient with a history of Werner syndrome: The main features were arteriosclerosis of the small intracerebral arteries, cerebral atrophy and vascular myelopathy. In addition, there were marked lipofuscin deposition and corpora amylacea, but no neurofibrillary tangles or plaques. In comparison with pathological findings in other organ systems, the central nervous system shows mainly degenerative pathology in this disease.
Brain↗